CA2463821A1 — Amide derivatives as glycogen synthase kinase 3-beta inhibitors

USPTO Abstract

This invention concerns a compound of formula (I' ),a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein ring A represents a 6-member ed heterocycle; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; optionally substituted C1-6alkyl; C1-6alkyloxycarbonyl; optionally substituted C1- 6alkyloxyC1-6alkylcarbonyl; X is a direct bond or a linker atom or group; Z is O or S; R2 is hydrogen, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, a carbocycle or a heterocycle, each of said groups may optionally be substituted; R3 is hydrogen; hydroxy; halo; optionally substituted C1-6alkyl or C2-6alkenyl or C2- 6alkynyl; C1-6alkyloxy; C1-6alkylthio; C1-6alkyloxycarbonyl; C1- 6alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amin o; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; polyhaloC1-6alkylthio; R21; R21-C1- 6alkyl; R21-O-; R21-S-; R21-C(=O)-; R21-S(=O)p-; R7-S(=O)p-; R7-S(=O)p-NH-; R21-S(=O)p-NH-; R7-C(=O)-; -NHC(=O)H;-C(=O)NHNH2; R7-C(=O)-NH-; R21-C(=O)-NH -; -C(=NH)R7; -C(=NH)R21 ; R4a or R4b each independently represent hydrogen, R8 , - Y1-NR9-Y2-NR10R11, -Y1-NR9-Y1-R8, -Y1-NR9R10; provided that -X-R2 and/or R3 is other than hydrogen; their use, pharmaceutical compositions comprising them and processes for their preparation.